Navigation Links
Dasatinib Shows High Early Response Rate as First Treatment for,Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, eva luated their data. They found that 77 percent of patients at three months, 92 percent at six months and 95 percent at one year had a complete cytogenetic response.

This rapid response compares favorably to historical data on patients at M. D. Anderson who took imatinib as a first therapy, Atallah noted. Imatinib's complete response rates at six months are 54 percent at 400 mg daily and 85 percent for 800 mg daily. However, at 12 months, 72 percent of patients receiving imatinib 400 mg and 92 percent of those receiving 800 mg had a complete cytogenetic response.

Dasatinib side effects have been manageable and mainly low-grade, with 15 patients having to temporarily stop treatment.

The M. D. Anderson clinical trial is set to enroll 100 patients. The comparison to historical data provides insight into dasatinib's effect, but a randomized clinical trial comparing medications directly would present a more detailed picture.

Imatinib, known commercially as Gleevec and produced by Novartis Pharmaceuticals, was the first drug to target the fusion protein BCR-ABL that causes the disease. Before Gleevec, the median five-year survival rate for CML patients was 50 percent. Researchers reported last year that the five-year survival rate of patients taking imatinib is 95 percent.

About 4,500 people receive a diagnosis of CML in the United States each year, and an estimated 20,500 people are living with the disease, according to the Leukemia & Lymphoma Society.

Co-investigators with Atallah are senior researcher Jorge Cortes, M.D., Hagop Kantarjian, M.D., Susan O'Brien, M.D., and Gautam Borthakur, M.B.B.S., all of the M. D. Anderson Department of Leukemia; Daniel Jones, M.D., Ph.D., of the M. D. Anderson Department of Hematopathology; and Claude Nicaise, M.D., of Bristol-Myers Squib Co.

Bristol-Myers sponsors the clinical trial.

Cortes reports having received research grants from Bristol-Myers Squibb. Kantarjian reports ha ving received lecture fees and research grants from Bristol-Myers Squibb. These arrangements are managed by M. D. Anderson in accordance with its conflict of interest policies.

- 30 -

Contact: Laura Sussman 713-745-2457; AT ASCO: 832-264-8893;

M. D. Anderson External Communications Office Media Hotline: (713) 792-0655


Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:12/1/2015)...  Athletic apparel company Tommie Copper , ... $1.35 million to settle Federal Trade Commission charges ... clothing would relieve severe and chronic pain and ... Tommie Copper,s proposed settlement with ... founder and chairman Thomas Kallish to ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... to a new market research report "Nucleic Acid Labeling ... Techniques (PCR, Nick Translation, Random Primer, In Vitro Transcription, ... to 2020", published by MarketsandMarkets, The global market is ... USD 1,271.8 Million in 2015, growing at a CAGR ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... ... 2015 , ... December 1, 2015 -- InstantLabs is adding ... product line of food safety and seafood fraud prevention tools. , The new ... InstantLabs to offer fast, reliable species identification for the four most popular salmon. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first ... Annual Meeting from November 29 to December 4, 2015. , MED-TAB is ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, 2015 ... price per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) ... provides software engineering, infrastructure, as well as operations and sustainment support to the ...
Breaking Medicine News(10 mins):